5 things to know about the new obesity pills that are on the way

Novo Nordisk and Eli Lilly are racing to bring oral obesity therapies to market, with Novo’s higher-dose semaglutide pill producing a 16.6% average weight loss over 64 weeks and Lilly’s orforglipron showing 12.4% at its top dose over 72 weeks. Novo’s oral semaglutide is expected to seek FDA approval before year-end while Lilly plans a submission this year and secured a priority review voucher; both companies agreed to offer approved oral versions direct-to-consumer at $149/month. The pills are daily (versus weekly injectables), have similar GI side effects, and could broaden access and pressure pricing for $1,000+/month injectable competitors; Pfizer’s acquisition of Metsera (potentially >$10bn) underscores strategic consolidation in the obesity pipeline.

Analysis

Market structure: Novo Nordisk (NVO) is the primary winner given semaglutide parity to Wegovy and an earlier expected approval window (months). Lower per-patient price ($149 DTC vs >$1,000 injectables) implies downward pressure on injected-product pricing and gross margins across the GLP-1 class; payers will favor pills, potentially converting 10–30% of current injectable users to oral therapy within 12 months if coverage expands.

Risk assessment: Key tail risks are an FDA safety signal or rejection (0–10% low-probability / high-impact), PBM/insurer non-coverage, and slower-than-expected adherence causing lower recurring revenue; catalyst calendar is concentrated in the next 60–120 days (filings/reviews), while next-gen agents (retatrutide, cagrilintide combos) present 2–4 year competitive risk. Hidden dependencies include SNAC supply chain, formulary placement timelines, and manufacturer direct-to-consumer fulfillment infrastructure.

Trade implications: Tactical trades favor NVO long exposure and relative shorts of slower/effectively weaker molecules (LLY/orforglipron) into approval windows. Use defined-risk options to capture binary FDA outcomes: buy 9–12 month call spreads on NVO sized 1–2% notional and maintain small protective put hedges (5–10% of equity stake) against regulatory blow-ups; accumulate PFE (1–2%) as a diversified, lower-volatility play on Metsera assets over 12–24 months.

Contrarian angles: Consensus underestimates payer-driven price caps (the $149 direct deal is a de facto ceiling for list pricing), so revenue modeling that assumes sustained $500+ ASPs is likely overstated. Conversely, uptake could be underappreciated in weight-loss-naïve populations—if two of top 3 PBMs place the pill on formulary inside 90 days, 2026 market share could skew heavily to pills, amplifying upside for NVO and pressuring injectables' manufacturers.

Key Decisions for Investors

• Establish a 2–3% long position in NVO ahead of the FDA decision window (next 60–120 days). Take profits to reduce to ~1% within 1–2 weeks after approval, or trim to 0.5% if approval is delayed >90 days.
• Implement a pair trade: long NVO (2% notional) vs short LLY (1.5–2% notional) to express relative efficacy/first-mover advantages; hold 6 months post-launch and close if LLY secures national formulary coverage from ≥2 of the top 3 PBMs within 90 days.
• Buy a defined-risk 9–12 month NVO call spread (~25% OTM) sized ~1% notional to capture approval upside while limiting premium; simultaneously buy 6–9 month OTM puts equal to 5–10% of the equity position as tail-risk insurance against safety/regulatory shocks.
• Accumulate PFE (1–2% core position) on the Metsera acquisition thesis as a lower-volatility, multi-year exposure to obesity pipeline assets; add incrementally if Phase-3 readouts for complementary molecules (cagrilintide/retatrutide) read positive in 12–36 months.
• Conditional scaling rule: monitor payer/formulary moves and script velocity for 30/60/90 days — if ≥2 major PBMs add the oral semaglutide within 90 days, increase NVO exposure to 4% and unwind the LLY short to neutral; if no major PBM coverage in 90 days, reduce NVO to 0.5% and close related options.